OTEurope

Highlights from AAO 2007

Nov 27, 2007

Article

Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA.

Related Videos

Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany

Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London

Kasperi Kankare at the iCare booth at ESCRS

Scott D Barnes, MD, CMO of STAAR Surgical

Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO

Colman Cawe, director of fundraising and communications, Orbis UK

Greg Kunst, CEO of Aurion Biotech

Related Content

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Related Content

A child wearing glasses sits in a classroom among her peers who do not have glasses. Image credit: ©Drazen – stock.adobe.com

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Research from Orbis International analyses the overall wellbeing of children with common childhood vision problems

A cell, as imaged under a microscope. Image credit: ©vipman4 – stock.adobe.com

Intravitreal cell therapy as protection from degenerations

September 18th 2023

Stem cells may replace some lost retinal neurons

A digital illustration of an eye with charts and numbers imposed atop it. Image credit: ©ArticMinimal – stock.adobe.com

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

The AI retinal scanning model will be free to use for all institutions

A group of doctors and scientists walk through a laboratory. Image credit: ©Oostendorp/peopleimages.com – stock.adobe.com

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

A series of test tubes in a laboratory. Image credit: ©Vladislava – stock.adobe.com

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

A patient administers eye drops to his own eye. Image credit: ©Krakenimages.com – stock.adobe.com

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.